Effect Of Piperine In Patients With Oropharyngeal Dysphagia (FIS 2009_2)
Primary Purpose
Deglutition Disorders
Status
Completed
Phase
Phase 1
Locations
Spain
Study Type
Interventional
Intervention
Piperine
Sponsored by
About this trial
This is an interventional treatment trial for Deglutition Disorders
Eligibility Criteria
Inclusion Criteria:
- Age>18
- History of swallowing difficulties associated with aging and/or neurological diseases (neurodegenerative or non-progressive neurological diseases)
- Study explained and written subject information given
- Informed consent signed
Exclusion Criteria:
- Patients suffering idiosyncratic phenomena or who are allergic to any medication, especially iodinated contrast media
- Patients suffering major respiratory disease or undergoing any type of surgery in the three months prior to the study
- Patients with a background of alcohol dependence or other drug dependence
- Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of the study
Sites / Locations
- Hospital de Mataró
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Piperine Dose 1
Piperine Dose 2
Arm Description
Piperine 1 mM
Piperine 150 microM
Outcomes
Primary Outcome Measures
Safety of swallow
Prevalence of penetrations at the laryngeal vestibule
Secondary Outcome Measures
Efficacy of swallow
Prevalence of oral and pharyngeal residue
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01383694
Brief Title
Effect Of Piperine In Patients With Oropharyngeal Dysphagia
Acronym
FIS 2009_2
Official Title
Effect of Natural Agonists of TRPV1 in the Treatment of Functional Oropharyngeal Dysphagia in Neurological Diseases and the Elderly: Piperine
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital de Mataró
4. Oversight
5. Study Description
Brief Summary
Piperine acts on the oropharyngeal TRPV1, increasing sensory input and the release of substance P. These actions may accelerate the oropharyngeal swallow response, improving the swallowing of dysphagic patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Deglutition Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Piperine Dose 1
Arm Type
Experimental
Arm Description
Piperine 1 mM
Arm Title
Piperine Dose 2
Arm Type
Experimental
Arm Description
Piperine 150 microM
Intervention Type
Drug
Intervention Name(s)
Piperine
Primary Outcome Measure Information:
Title
Safety of swallow
Description
Prevalence of penetrations at the laryngeal vestibule
Time Frame
15 minutes
Secondary Outcome Measure Information:
Title
Efficacy of swallow
Description
Prevalence of oral and pharyngeal residue
Time Frame
15 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age>18
History of swallowing difficulties associated with aging and/or neurological diseases (neurodegenerative or non-progressive neurological diseases)
Study explained and written subject information given
Informed consent signed
Exclusion Criteria:
Patients suffering idiosyncratic phenomena or who are allergic to any medication, especially iodinated contrast media
Patients suffering major respiratory disease or undergoing any type of surgery in the three months prior to the study
Patients with a background of alcohol dependence or other drug dependence
Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of the study
Facility Information:
Facility Name
Hospital de Mataró
City
Mataró
State/Province
Barcelona
ZIP/Postal Code
08304
Country
Spain
12. IPD Sharing Statement
Links:
URL
http://link.springer.com/article/10.1007%2Fs00535-013-0920-0
Description
Publication
Learn more about this trial
Effect Of Piperine In Patients With Oropharyngeal Dysphagia
We'll reach out to this number within 24 hrs